SCHEMBL19781272

SCHEMBL19781272

CC(C)Oc1ccc(-c2cnc3ncc(-c4ccc5[nH]ccc5c4)n3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 4/20 0.43
CCNT1 O60563 4/20 0.43
CDK9 P50750 4/20 0.43
CDK5 Q00535 4/20 0.43
DYRK1A Q13627 4/20 0.43
CDK5R1 Q15078 4/20 0.43
DYRK2 Q92630 4/20 0.43
DYRK1B Q9Y463 4/20 0.43
CCNA2 P20248 3/20 0.41
CDK2 P24941 3/20 0.41
CHRNA7 P36544 3/20 0.41
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
CHRNA10 Q9GZZ6 2/20 0.41
CHRNA9 Q9UGM1 2/20 0.41
CHEK1 O14757 4/20 0.41
CHEK2 O96017 3/20 0.41
ABL1 P00519 1/20 0.41
LRRK2 Q5S007 2/20 0.39
PTGS2 P35354 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781167 0.87 DYRK3 (0.51) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL19781802 0.85 DYRK1A (0.48) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL19781270 0.84 CHEK1 (0.48) CHEK1CHEK2ABL1FYNMAP4K4
SCHEMBL19781579 0.81 FYN (0.47) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL19781131 0.77 CLK1 (0.41) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL19781262 0.73 CHRNB4 (0.39) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL19781581 0.71 MAP4K4 (0.41) DYRK3CDK5DYRK1ACDK2CHEK1
SCHEMBL21436049 0.71 MAPT (0.43) DYRK1ACHEK1CHEK2ABL1FYN
SCHEMBL19781133 0.70 RIPK2 (0.48) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL3025365 0.70 MAOA (0.55) PTGS2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 DYRK3 4529/4885CCNT1 381/4885CDK9 2002/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S DYRK3 4459/4885CCNT1 423/4885CDK9 2015/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S DYRK3 4459/4885CCNT1 423/4885CDK9 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.